Characterization of a rare EGFR resistance mutation in a lung cancer patient with a long response to osimertinib: case report [0.03%]
奥希替尼长期治疗一例罕见的EGFR耐药突变型肺癌患者的病例报告及特征分析
Beatriz García-Peláez,Núria Jordana-Ariza,Andrés Aguilar-Hernández et al.
Beatriz García-Peláez et al.
Introduction: Osimertinib is the standard of care in first-line therapy for advanced EGFR-mutant NSCLC, but resistance invariably develops through EGFR-dependent or independent mechanisms. ...
Real-world burden of cardiovascular events following immune checkpoint inhibitor therapy: impact on mortality and treatment resumption in 29,503 patients [0.03%]
免疫检查点抑制剂治疗后心血管事件的现实世界负担：对29,503例患者死亡率和恢复治疗的影响
Clemence Rigaux,Dimitri Arangalage,Karissa Adkins et al.
Clemence Rigaux et al.
Background: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but can cause rare, severe cardiotoxicity. The real-world incidence and impact of a broader spectrum of cardiovascular events remains poorly ...
Osimertinib after definitive CRT in unresectable stage III EGFR-mutated NSCLC: safety outcomes from the phase III LAURA study [0.03%]
针对无法手术的III期EGFR突变型NSCLC患者在确定性同期放化疗后使用奥希替尼：LAURA三期临床试验的安全性结果分析
Terufumi Kato,Xiaorong Dong,Toshiaki Takahashi et al.
Terufumi Kato et al.
Background: In the phase III LAURA study, osimertinib demonstrated a statistically significant progression-free survival benefit versus placebo, and a generally tolerable safety profile, after definitive chemoradiotherapy...
Rechallenge with zongertinib after trastuzumab deruxtecan in HER2-mutant lung cancer: A case report [0.03%]
恩美曲妥珠单抗治疗后使用ゾンゲルチニブ治疗HER2突变型肺癌的挽救性治疗：一例报告
Hayato Koba,Yuichi Tambo,Yuya Murase et al.
Hayato Koba et al.
A 65-year-old man with advanced lung adenocarcinoma underwent comprehensive genomic profile testing using a blood sample after completion of standard therapy, which identified a HER2 mutation. The HER2- tyrosine kinase inhibitor (TKI); zong...
Comparative performance of shape-sensing robotic-assisted bronchoscopy and CT-guided transthoracic biopsy in diagnosing peripheral pulmonary lesions [0.03%]
形状感应机器人辅助支气管镜与CT引导下经胸穿刺活检诊断肺外周病变的性能比较
Dakota McNierney,Cody Messick,Morgan Reeve et al.
Dakota McNierney et al.
Background: Lung cancer is the leading cause of cancer mortality. Nonsurgical biopsies are obtained by computed tomography-guided transthoracic biopsy (CTTB) or bronchoscopically. Due to previous limitations in convention...
Refining N1 classification: prognostic validation of N1 subdivision in resected non-small cell lung cancer [0.03%]
NSCLC根治术后N1分期的预后分析及分组优化研究
Shia Kim,In Ha Kim,Ji Yong Kim et al.
Shia Kim et al.
Introduction: Accurate evaluation of nodal metastasis is essential for staging and prognostication of non-small cell lung cancer (NSCLC). The 9th edition of the TNM classification subdivided N2 into single station(N2a) an...
European experience on oncological outcomes of patients with early-stage non-small cell lung cancer and any prior cancer following lobectomy or segmentectomy [0.03%]
欧洲早期非小细胞肺癌术前任何部位肿瘤患者 lobectomy 或段切术后预后的经验教训
Lukadi Joseph Lula,Rita Costa,Lin Huang et al.
Lukadi Joseph Lula et al.
Objectives: To assess the impact of lung resection extent on early-stage non-small cell lung cancer with a history of any cancer. Methods: ...
Multicenter Study
Lung cancer (Amsterdam, Netherlands). 2026 Jul:217:109410. DOI:10.1016/j.lungcan.2026.109410 2026
Real-world clinical characteristics and outcomes in patients with HER2-mutant non-small cell lung cancer (NSCLC) who received second-line treatment: A nationwide database analysis in Japan [0.03%]
接受二线治疗的HER2突变型非小细胞肺癌（NSCLC）患者的真实世界临床特征及预后：一项日本全国数据库分析
Yuji Uehara,Masachika Ikegami,Shinji Kohsaka et al.
Yuji Uehara et al.
Background: Although human epidermal growth factor receptor 2 (HER2)-targeted therapies have been approved for HER2-mutant NSCLC, real-world outcome data especially in the second-line setting remains limited. ...
Integrating chest CT-derived skeletal muscle index with SARC-F for sarcopenia screening in patients with lung cancer [0.03%]
结合胸部CT衍生的骨骼肌指数和SARC-F进行肺癌患者的肌少症筛查
Huiwen Weng,Yinghong Li,Lianyue Yang et al.
Huiwen Weng et al.
Aims: To evaluate and compare the diagnostic performance of thoracic computed tomography (CT)-derived skeletal muscle indexes (SMIs), used alone and combined with the SARC-F questionnaire, for identifying sarcopenia in lu...
Development of a clinical prediction model using digital device data for interstitial lung disease in patients with unresectable stage III non-small cell lung cancer treated with durvalumab [0.03%]
使用数字设备数据开发临床预测模型以预测不可切除III期非小细胞肺癌患者接受度伐卢单抗治疗后间质性肺病的发生
Satoshi Ikeda,Hirotsugu Kenmotsu,Ryo Koto et al.
Satoshi Ikeda et al.
Background: Early detection of interstitial lung disease including radiation pneumonitis (ILD/RP) is crucial in consolidative durvalumab therapy after chemoradiotherapy (CRT) in unresectable stage III non-small cell lung ...